Literature DB >> 26577926

Peptidyl Arginine Deiminases and Neurodegenerative Diseases.

R Tu, H M Grover, L P Kotra1.   

Abstract

Peptidyl arginine deiminases (PADs) are a small group of isozymes that convert Arg residues on the surface of proteins into citrulline residues, typically as a part of posttranslational processing. PADs are present in most of the tissues, and the isozyme distribution is tissue-specific. In the past 15 years, it is becoming apparent that PADs are either upregulated or their catalytic activity is enhanced in certain disease conditions, including neurological diseases. In particular, hypercitrullinated proteins and elevated PAD activities are discovered in neurodegenerative conditions such as multiple sclerosis, Alzheimer's disease etc. This review article reviews the status of PAD enzymes as targets in neurodegenerative conditions, and briefly outlines the efforts in medicinal chemistry to identify PAD inhibitors for the treatment of various neurodegenerative conditions.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26577926     DOI: 10.2174/0929867323666151118120710

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  4 in total

1.  Assessment of Neurodegenerative Changes in Turkeys Fed Diets with Different Proportions of Arginine and Methionine Relative to Lysine.

Authors:  Magdalena Krauze; Katarzyna Ognik; Dariusz Mikulski; Jan Jankowski
Journal:  Animals (Basel)       Date:  2022-06-14       Impact factor: 3.231

2.  Peptidylarginine Deiminase 2 Autoantibodies Are Linked to Less Severe Disease in Multiple Sclerosis and Post-treatment Lyme Disease.

Authors:  Yaewon Kim; Alison W Rebman; Tory P Johnson; Hong Wang; Ting Yang; Carlo Colantuoni; Pavan Bhargava; Michael Levy; Peter A Calabresi; John N Aucott; Mark J Soloski; Erika Darrah
Journal:  Front Neurol       Date:  2022-06-06       Impact factor: 4.086

Review 3.  Peptidyl Arginine Deiminase 2 (PADI2)-Mediated Arginine Citrullination Modulates Transcription in Cancer.

Authors:  Miguel Beato; Priyanka Sharma
Journal:  Int J Mol Sci       Date:  2020-02-17       Impact factor: 6.208

4.  Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.

Authors:  Lidong Liu; Zhiwei Zhang; Guoxiang Zhang; Ting Wang; Yingchun Ma; Wei Guo
Journal:  J Transl Med       Date:  2020-09-20       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.